calcium acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4287	62-54-4

Description:

Molecule	Description
Synonyms: calcium acetate acetic acid calcium salt calcium diacetate calcium acetate anhydrous	a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer Molecular weight: 158.17 Formula: C4H6CaO4 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 40.13 ALOGS: ROTB: None

Molecule

Description

Synonyms:

calcium acetate
acetic acid calcium salt
calcium diacetate
calcium acetate anhydrous

a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer

Molecular weight: 158.17
Formula: C4H6CaO4
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 40.13
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
6	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 6, 1982	FDA	B BRAUN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	265.95	13.93	72	9232	4484	63475234
Skin induration	120.55	13.93	36	9268	3187	63476531
Peritonitis bacterial	117.76	13.93	39	9265	4840	63474878
Skin hypertrophy	97.68	13.93	31	9273	3360	63476358
Calciphylaxis	92.29	13.93	29	9275	3043	63476675
Skin tightness	82.61	13.93	29	9275	4287	63475431
Skin fibrosis	61.28	13.93	16	9288	864	63478854
Chronic kidney disease	59.64	13.93	51	9253	45347	63434371
Peritonitis	57.12	13.93	34	9270	17120	63462598
Skin hyperpigmentation	50.02	13.93	22	9282	5899	63473819
Dialysis	49.25	13.93	26	9278	10401	63469317
Blood phosphorus increased	48.45	13.93	18	9286	3127	63476591
Haemodialysis	47.11	13.93	24	9280	8923	63470795
Fibrosis	46.83	13.93	19	9285	4173	63475545
Hypervolaemia	45.87	13.93	36	9268	28377	63451341
Blood parathyroid hormone increased	41.77	13.93	16	9288	3022	63476696
Hypercalcaemia	39.61	13.93	33	9271	28289	63451429
Joint contracture	38.49	13.93	13	9291	1711	63478007
Drug ineffective	31.98	13.93	66	9238	1044699	62435019
Haemodialysis complication	30.76	13.93	7	9297	211	63479507
Hypocalcaemia	30.63	13.93	30	9274	31683	63448035
Milk-alkali syndrome	29.88	13.93	9	9295	819	63478899
End stage renal disease	29.66	13.93	16	9288	6677	63473041
Aplasia pure red cell	29.48	13.93	14	9290	4473	63475245
Peau d'orange	27.68	13.93	6	9298	144	63479574
Extremity contracture	25.99	13.93	9	9295	1276	63478442
Scar	25.62	13.93	19	9285	13763	63465955
Drug intolerance	25.25	13.93	7	9297	308654	63171064
Skin discolouration	24.56	13.93	29	9275	37799	63441919
Haemoglobin decreased	24.53	13.93	61	9243	145424	63334294
Oedema peripheral	24.47	13.93	72	9232	189439	63290279
Cardiac failure congestive	23.84	13.93	46	9258	92387	63387331
Azotaemia	23.56	13.93	12	9292	4459	63475259
Peritoneal dialysis complication	22.59	13.93	8	9296	1212	63478506
Product use issue	22.23	13.93	3	9301	220517	63259201
Anti-erythropoietin antibody positive	21.63	13.93	6	9298	408	63479310
Renal failure	21.61	13.93	51	9253	117601	63362117
Sepsis	21.53	13.93	60	9244	153063	63326655
Blood erythropoietin decreased	21.41	13.93	3	9301	3	63479715
Hyperparathyroidism secondary	21.15	13.93	8	9296	1459	63478259
Hypotension	20.78	13.93	87	9217	272517	63207201
Brown tumour	20.77	13.93	4	9300	52	63479666
Unresponsive to stimuli	20.44	13.93	25	9279	33791	63445927
Off label use	20.22	13.93	43	9261	674419	62805299
Therapeutic response decreased	20.18	13.93	34	9270	61491	63418227
Joint range of motion decreased	19.64	13.93	24	9280	32404	63447314
Treatment failure	19.38	13.93	3	9301	199040	63280678
Hyperparathyroidism	19.37	13.93	9	9295	2740	63476978
Skin plaque	18.99	13.93	13	9291	8307	63471411
Sinusitis	18.79	13.93	5	9299	226648	63253070
Systemic lupus erythematosus	18.51	13.93	4	9300	208914	63270804
Anaemia	18.13	13.93	88	9216	293342	63186376
Emotional distress	17.97	13.93	23	9281	32526	63447192
Product use in unapproved indication	16.77	13.93	3	9301	179077	63300641
Glossodynia	16.74	13.93	3	9301	178873	63300845
Fungal peritonitis	15.91	13.93	5	9299	524	63479194
Anhedonia	15.78	13.93	13	9291	10961	63468757
Synovitis	15.73	13.93	4	9300	186914	63292804
Nausea	15.53	13.93	192	9112	854279	62625439
Serum ferritin increased	14.92	13.93	10	9294	6172	63473546
Hyperphosphataemia	14.73	13.93	7	9297	2241	63477477
Infusion related reaction	14.55	13.93	9	9295	245512	63234206
Pulmonary calcification	14.53	13.93	4	9300	264	63479454
Mental status changes	14.49	13.93	23	9281	39576	63440142
Joint swelling	14.49	13.93	16	9288	327650	63152068
Acute phase reaction	14.32	13.93	4	9300	279	63479439
Ocular icterus	14.17	13.93	8	9296	3648	63476070

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	227.64	16.34	70	8789	3935	34944137
Peritonitis bacterial	157.51	16.34	59	8800	6051	34942021
Skin induration	123.91	16.34	38	8821	2113	34945959
Skin hypertrophy	112.37	16.34	37	8822	2592	34945480
Skin tightness	93.45	16.34	31	8828	2222	34945850
Joint contracture	85.42	16.34	28	8831	1933	34946139
Joint range of motion decreased	75.70	16.34	37	8822	7275	34940797
Skin fibrosis	70.99	16.34	21	8838	1031	34947041
Peritonitis	59.47	16.34	42	8817	16323	34931749
Scar	58.32	16.34	29	8830	5915	34942157
Peritoneal dialysis complication	49.54	16.34	18	8841	1691	34946381
Fibrosis	49.42	16.34	20	8839	2516	34945556
Hypervolaemia	46.21	16.34	39	8820	19670	34928402
Extremity contracture	45.57	16.34	14	8845	782	34947290
Calciphylaxis	41.22	16.34	14	8845	1078	34946994
Blood parathyroid hormone increased	40.39	16.34	15	8844	1499	34946573
Chronic kidney disease	38.83	16.34	50	8809	41160	34906912
Anhedonia	38.54	16.34	24	8835	7561	34940511
Dialysis	36.67	16.34	27	8832	11181	34936891
Respiratory tract infection bacterial	34.54	16.34	14	8845	1768	34946304
Emotional distress	33.72	16.34	29	8830	14997	34933075
Aplasia pure red cell	32.67	16.34	20	8839	6112	34941960
Respiratory tract infection viral	29.89	16.34	14	8845	2503	34945569
Cardiac arrest	29.42	16.34	71	8788	96088	34851984
Deformity	29.27	16.34	12	8847	1560	34946512
Haemodialysis	29.24	16.34	23	8836	10503	34937569
Joint stiffness	26.48	16.34	22	8837	10851	34937221
Skin hyperpigmentation	26.44	16.34	14	8845	3250	34944822
Injury	25.88	16.34	29	8830	20658	34927414
Therapeutic response decreased	25.18	16.34	34	8825	29279	34918793
Renal failure	24.74	16.34	81	8778	130476	34817596
Peau d'orange	24.33	16.34	6	8853	146	34947926
Complication associated with device	23.17	16.34	16	8843	5990	34942082
Skin discolouration	22.29	16.34	25	8834	17820	34930252
Fungal peritonitis	21.78	16.34	8	8851	775	34947297
Haemoglobin decreased	21.16	16.34	73	8786	120699	34827373
Blood potassium increased	20.42	16.34	23	8836	16472	34931600
Arteriovenous fistula occlusion	19.64	16.34	5	8854	139	34947933
Off label use	19.55	16.34	49	8810	419475	34528597
Fractured skull depressed	19.54	16.34	4	8855	40	34948032
Choreoathetosis	19.39	16.34	8	8851	1056	34947016
Mobility decreased	18.72	16.34	30	8829	30098	34917974
Azotaemia	18.62	16.34	13	8846	4954	34943118
Drug ineffective	18.57	16.34	57	8802	456694	34491378
Anti-erythropoietin antibody positive	17.24	16.34	7	8852	888	34947184
Haemorrhagic ovarian cyst	16.83	16.34	4	8855	83	34947989
Refractory cytopenia with unilineage dysplasia	16.73	16.34	6	8853	543	34947529

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	351.25	14.15	100	14310	6060	79723918
Peritonitis bacterial	271.68	14.15	91	14319	9476	79720502
Skin induration	181.62	14.15	56	14354	4469	79725509
Skin hypertrophy	172.77	14.15	55	14355	4873	79725105
Skin tightness	150.72	14.15	51	14359	5471	79724507
Calciphylaxis	131.84	14.15	42	14368	3728	79726250
Peritonitis	116.40	14.15	69	14341	27967	79702011
Skin fibrosis	106.35	14.15	29	14381	1495	79728483
Joint contracture	100.28	14.15	31	14379	2493	79727485
Chronic kidney disease	82.29	14.15	79	14331	66075	79663903
Peritoneal dialysis complication	77.29	14.15	25	14385	2329	79727649
Hypervolaemia	75.03	14.15	62	14348	42628	79687350
Haemodialysis	68.39	14.15	42	14368	18126	79711852
Dialysis	65.25	14.15	41	14369	18421	79711557
Joint range of motion decreased	57.78	14.15	48	14362	33234	79696744
Fibrosis	57.49	14.15	25	14385	5284	79724694
Scar	56.87	14.15	35	14375	15161	79714817
Blood parathyroid hormone increased	53.53	14.15	21	14389	3424	79726554
Skin hyperpigmentation	52.84	14.15	26	14384	7277	79722701
Extremity contracture	39.53	14.15	14	14396	1718	79728260
Hypercalcaemia	38.79	14.15	41	14369	38389	79691589
Renal failure	38.77	14.15	101	14309	200867	79529111
Skin discolouration	38.29	14.15	42	14368	40992	79688986
Aplasia pure red cell	37.13	14.15	21	14389	7789	79722189
Respiratory tract infection bacterial	37.05	14.15	14	14396	2063	79727915
Peau d'orange	35.82	14.15	9	14401	336	79729642
Cardiac arrest	35.80	14.15	89	14321	172007	79557971
Anhedonia	35.67	14.15	26	14384	14872	79715106
End stage renal disease	35.49	14.15	24	14386	12196	79717782
Drug ineffective	34.43	14.15	92	14318	1080821	78649157
Completed suicide	33.39	14.15	3	14407	245764	79484214
Azotaemia	33.37	14.15	20	14390	8256	79721722
Emotional distress	32.35	14.15	38	14372	39931	79690047
Off label use	32.17	14.15	73	14337	907142	78822836
Hypocalcaemia	31.66	14.15	42	14368	49882	79680096
Haemodialysis complication	31.45	14.15	8	14402	314	79729664
Unresponsive to stimuli	30.96	14.15	44	14366	55744	79674234
Haemoglobin decreased	30.64	14.15	99	14311	222020	79507958
Fungal peritonitis	29.38	14.15	10	14400	1090	79728888
Blood phosphorus increased	29.28	14.15	20	14390	10327	79719651
Respiratory tract infection viral	27.39	14.15	14	14396	4245	79725733
Joint stiffness	26.89	14.15	35	14375	40795	79689183
Hypotension	26.79	14.15	153	14257	440164	79289814
Deformity	25.85	14.15	18	14392	9587	79720391
Anti-erythropoietin antibody positive	25.12	14.15	8	14402	709	79729269
Pulmonary calcification	24.33	14.15	7	14403	439	79729539
Drug intolerance	23.77	14.15	9	14401	264110	79465868
Cardiac failure congestive	22.91	14.15	67	14343	142335	79587643
Arteriovenous fistula occlusion	22.86	14.15	7	14403	545	79729433
Arteriovenous fistula thrombosis	22.63	14.15	7	14403	564	79729414
Blood potassium increased	22.32	14.15	27	14383	29248	79700730
Hyperphosphataemia	22.12	14.15	14	14396	6362	79723616
Oedema peripheral	21.92	14.15	97	14313	252191	79477787
Transferrin saturation increased	21.49	14.15	5	14405	134	79729844
Sepsis	21.48	14.15	101	14309	269327	79460651
Arteriovenous fistula operation	21.07	14.15	6	14404	363	79729615
Fractured skull depressed	20.89	14.15	4	14406	40	79729938
Complication associated with device	20.07	14.15	20	14390	17476	79712502
Nephrogenic anaemia	19.93	14.15	11	14399	3891	79726087
Milk-alkali syndrome	19.78	14.15	8	14402	1412	79728566
Brown tumour	19.72	14.15	4	14406	55	79729923
Skin plaque	19.69	14.15	16	14394	10729	79719249
Choreoathetosis	19	14.15	8	14402	1562	79728416
Arteriovenous fistula site complication	18.86	14.15	7	14403	982	79728996
Mental status changes	18.77	14.15	39	14371	66920	79663058
Serum ferritin increased	18.76	14.15	15	14395	9832	79720146
Asthenia	18.73	14.15	157	14253	511532	79218446
Anaemia	18.72	14.15	141	14269	444874	79285104
Ultrafiltration failure	18.35	14.15	5	14405	257	79729721
Kidney transplant rejection	18.24	14.15	15	14395	10231	79719747
Transferrin saturation decreased	17.85	14.15	7	14403	1139	79728839
Product use issue	17.50	14.15	8	14402	209814	79520164
Peripheral swelling	17.30	14.15	14	14396	269603	79460375
Treatment noncompliance	16.51	14.15	32	14378	52236	79677742
Skin disorder	16.27	14.15	25	14385	33918	79696060
Product use in unapproved indication	16.07	14.15	13	14397	250346	79479632
Infusion related reaction	16.00	14.15	11	14399	230226	79499752
Pulseless electrical activity	15.89	14.15	16	14394	14144	79715834
Rheumatoid arthritis	15.82	14.15	9	14401	208461	79521517
Sclerodactylia	15.60	14.15	4	14406	162	79729816
Hypoglycaemia	15.57	14.15	47	14363	101547	79628431
Hyperparathyroidism secondary	14.98	14.15	8	14402	2652	79727326
Injury	14.97	14.15	39	14371	77457	79652521
Contraindicated product administered	14.79	14.15	5	14405	157533	79572445
Pulmonary oedema	14.64	14.15	42	14368	88212	79641766
Lower respiratory tract infection	14.21	14.15	3	14407	129217	79600761
Condition aggravated	14.16	14.15	45	14365	501079	79228899

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AE07	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
CHEBI has role	CHEBI:38161	Chelating agent
MeSH PA	D002614	Chelating Agents
MeSH PA	D064449	Sequestering Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypocalcemia	indication	5291005
Hyperkalemia	indication	14140009
Hypermagnesemia	indication	66978005
Hypocalcemic tetany	indication	190869004
Disorder of electrolytes	indication	237840007
Cardiac arrest	indication	410429000	DOID:0060319
Renal Osteodystrophy with Hyperphosphatemia	indication
Neonatal hypocalcemic tetany	off-label use	18442000
Poisoning by digitalis glycoside	contraindication	12876009
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Diarrhea	contraindication	62315008
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
667MG/5ML	PHOSLYRA	FRESENIUS MEDCL	N022581	April 18, 2011	DISCN	SOLUTION	ORAL	8592480	July 20, 2027	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
667MG/5ML	PHOSLYRA	FRESENIUS MEDCL	N022581	April 18, 2011	DISCN	SOLUTION	ORAL	9089528	July 20, 2027	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
667MG/5ML	PHOSLYRA	FRESENIUS MEDCL	N022581	April 18, 2011	DISCN	SOLUTION	ORAL	8591938	Feb. 23, 2030	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018721	VUID
N0000147026	NUI
D00931	KEGG_DRUG
4018721	VANDF
C0717537	UMLSCUI
CHEBI:59199	CHEBI
CHEMBL1200800	ChEMBL_ID
DB00258	DRUGBANK_ID
C120662	MESH_SUPPLEMENTAL_RECORD_UI
Y882YXF34X	UNII
6116	PUBCHEM_CID
214342	RXNORM
118	MMSL
4329	MMSL
d03689	MMSL
000772	NDDF
116118002	SNOMEDCT_US
387019008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0088	CAPSULE	667 mg	ORAL	ANDA	25 sections
ProcalAmine	HUMAN PRESCRIPTION DRUG LABEL	22	0264-1915	INJECTION	0.03 g	INTRAVENOUS	NDA	24 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8364	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2081	CAPSULE	667 mg	ORAL	NDA authorized generic	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2081	CAPSULE	667 mg	ORAL	NDA authorized generic	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2672	CAPSULE	667 mg	ORAL	NDA authorized generic	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2672	CAPSULE	667 mg	ORAL	NDA authorized generic	26 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6668	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7119	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-629	CAPSULE	667 mg	ORAL	ANDA	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	16571-813	CAPSULE	667 mg	ORAL	ANDA	19 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	16571-813	CAPSULE	667 mg	ORAL	ANDA	19 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0088	CAPSULE	667 mg	ORAL	ANDA	24 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0191	CAPSULE	667 mg	ORAL	ANDA	27 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0377	CAPSULE	667 mg	ORAL	ANDA	17 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-531	CAPSULE	667 mg	ORAL	ANDA	25 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-531	CAPSULE	667 mg	ORAL	ANDA	25 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-531	CAPSULE	667 mg	ORAL	ANDA	25 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-621	TABLET	667 mg	ORAL	ANDA	16 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-621	TABLET	667 mg	ORAL	ANDA	16 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	24689-793	CAPSULE	667 mg	ORAL	ANDA	19 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	29033-026	CAPSULE	667 mg	ORAL	ANDA	24 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-377	CAPSULE	667 mg	ORAL	ANDA	17 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-393	TABLET	667 mg	ORAL	ANDA	17 sections
PhosLo	HUMAN PRESCRIPTION DRUG LABEL	1	49230-640	CAPSULE	667 mg	ORAL	NDA	24 sections
PhosLo	HUMAN PRESCRIPTION DRUG LABEL	1	49230-640	CAPSULE	667 mg	ORAL	NDA	24 sections
Phoslyra	HUMAN PRESCRIPTION DRUG LABEL	1	49230-643	SOLUTION	667 mg	ORAL	NDA	26 sections
Phoslyra	HUMAN PRESCRIPTION DRUG LABEL	1	49230-643	SOLUTION	667 mg	ORAL	NDA	26 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0621	TABLET	667 mg	ORAL	ANDA	16 sections
Aluminum Acetate Astringent	HUMAN OTC DRUG LABEL	2	51224-153	POWDER, FOR SOLUTION	839 mg	TOPICAL	OTC MONOGRAPH FINAL	13 sections